Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress

TheFly reported connected January 5 that Wells Fargo raised its terms people connected TSHA to $11 from $8 and maintained an Overweight rating. The steadfast credited the anticipated 2026 outperformance to the ongoing advancements successful its superior Rett syndrome research, which are bolstered by the FDA’s support of a favorable proceedings plan past year.

Separately, connected January 6, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) reported advancement connected its TSHA-102 Rett syndrome program. The archetypal diligent successful the REVEAL pivotal signifier was dosed successful Q4 2025, and the FDA authorized the usage of ASPIRE proceedings information successful the projected BLA. With updated information and efficacy information from REVEAL Part A owed successful H1 2026, TSHA plans to implicit dosing successful some studies by Q2 2026.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is simply a clinical‑stage biotechnology institution that develops adeno‑associated microorganism (AAV)‑based cistron therapies for terrible monogenic diseases of the cardinal tense system, including Rett syndrome.

While we admit the imaginable of TSHA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.